Barry Greenberg Selected Research

Heart Diseases (Heart Disease)

3/2016	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
9/2015	Gene therapy for heart failure.
2/2014	Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
1/2014	Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
7/2011	Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
4/2009	Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barry Greenberg Research Topics

Disease

73	Heart Failure 02/2024 - 01/2003
13	Myocardial Infarction 12/2023 - 05/2006
12	Stroke (Strokes) 12/2023 - 07/2015
9	Coronary Artery Disease (Coronary Atherosclerosis) 12/2023 - 07/2015
6	Heart Diseases (Heart Disease) 03/2016 - 04/2009
4	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 07/2009
4	Hemorrhage 01/2021 - 01/2017
4	Atrial Fibrillation 01/2020 - 02/2014
3	Coronary Disease (Coronary Heart Disease) 11/2023 - 10/2018
3	Renal Insufficiency (Renal Failure) 01/2023 - 02/2012
3	Inflammation (Inflammations) 01/2023 - 07/2016
3	Disease Progression 01/2021 - 01/2016
3	Ventricular Remodeling 07/2011 - 07/2007
3	Left Ventricular Dysfunction 05/2010 - 05/2003
2	Dyspnea (Shortness of Breath) 01/2022 - 01/2010
2	Weight Loss (Weight Reduction) 01/2022 - 07/2010
2	Substance-Related Disorders (Drug Abuse) 03/2020 - 01/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 07/2004
1	Ischemic Stroke 11/2023
1	Edema (Dropsy) 01/2023
1	Craniofacial Abnormalities 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Cognitive Dysfunction 01/2023
1	Memory Disorders (Memory Loss) 01/2023
1	COVID-19 01/2022
1	Neoplasms (Cancer) 01/2021
1	Pulmonary Arterial Hypertension 01/2021
1	Venous Thromboembolism 01/2021
1	Anxiety Disorders (Anxiety Disorder) 03/2020
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020
1	Chronic Renal Insufficiency 01/2020
1	Alcoholism (Alcohol Abuse) 01/2020
1	Liver Diseases (Liver Disease) 12/2019
1	Death (Near-Death Experience) 01/2019
1	Pathologic Processes 05/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2017
1	Chronic Disease (Chronic Diseases) 01/2017
1	Body Weight Changes 04/2016

Drug/Important Bio-Agent (IBA)

10	RivaroxabanIBA 12/2023 - 07/2015
10	Biomarkers (Surrogate Marker)IBA 01/2023 - 11/2004
8	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2023 - 02/2010
7	CalciumIBA 03/2016 - 01/2003
5	DiureticsIBA 01/2023 - 01/2003
5	Natriuretic PeptidesIBA 03/2020 - 07/2015
5	Carvedilol (Coreg)FDA LinkGeneric 05/2007 - 01/2004
4	Mineralocorticoid Receptor AntagonistsIBA 01/2023 - 01/2018
4	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2021 - 01/2020
3	pro-brain natriuretic peptide (1-76)IBA 12/2023 - 04/2009
3	CreatinineIBA 01/2022 - 08/2007
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/2020 - 05/2003
3	RelaxinIBA 12/2019 - 02/2012
3	AldosteroneIBA 05/2010 - 05/2006
2	fibrin fragment D (D-dimer)IBA 12/2023 - 01/2021
2	Protein Isoforms (Isoforms)IBA 01/2023 - 02/2014
2	Angiotensin Receptor AntagonistsIBA 04/2020 - 01/2016
2	Neprilysin (Neutral Endopeptidase)IBA 04/2020 - 01/2016
2	Opioid Analgesics (Opioids)IBA 03/2020 - 01/2020
2	salicylhydroxamic acid (SHAM)IBA 01/2019 - 09/2010
2	Thrombin FDA Link 10/2018 - 07/2015
2	Deoxyribonucleases (DNase)FDA Link 03/2016 - 01/2014
2	Adenosine Triphosphatases (ATPase)IBA 02/2014 - 07/2011
2	Sarcoplasmic Reticulum Calcium-Transporting ATPasesIBA 01/2014 - 07/2011
2	Proteins (Proteins, Gene)FDA Link 10/2011 - 11/2004
2	Eplerenone (Inspra)FDA LinkGeneric 05/2010 - 05/2006
2	Vasodilator Agents (Vasodilators)IBA 09/2008 - 01/2003
2	Metoprolol (Toprol-XL)FDA LinkGeneric 07/2007 - 01/2004
1	dapagliflozinIBA 02/2024
1	empagliflozinIBA 01/2024
1	Adenosine Monophosphate (AMP)IBA 01/2024
1	Insulin (Novolin)FDA Link 12/2023
1	Collagen ReceptorsIBA 01/2023
1	C-Reactive ProteinIBA 01/2023
1	Apolipoprotein E4IBA 01/2023
1	IntegrinsIBA 01/2023
1	Discoidin Domain Receptor 2IBA 01/2023
1	Bumetanide (Bumex)FDA LinkGeneric 01/2023
1	Growth Differentiation Factor 15IBA 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	Furosemide (Lasix)FDA LinkGeneric 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2022
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 04/2020
1	insulin receptor-related receptor (IRR)IBA 01/2020
1	A-factor (Streptomyces)IBA 10/2018
1	Retinaldehyde (Retinal)IBA 03/2017
1	Warfarin (Coumadin)FDA LinkGeneric 01/2017
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017
1	AnticoagulantsIBA 01/2017
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2016
1	ElementsIBA 07/2015
1	rolofyllineIBA 05/2015

Therapy/Procedure

26	Therapeutics 11/2023 - 01/2004
6	Cutaneous Administration 03/2016 - 04/2009
5	Heart-Assist Devices 01/2020 - 11/2007
3	Patient Readmission 01/2023 - 02/2012
3	Length of Stay 05/2015 - 07/2004
2	Heart Transplantation (Grafting, Heart) 01/2019 - 01/2014
1	Investigational Therapies (Experimental Therapy) 01/2019
1	Immunotherapy 01/2019
1	Aftercare (After-Treatment) 10/2018